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Background: Multiple Sclerosis (MS) is an immune-mediated disease of the Central Nervous System with two major
underlying etiopathogenic processes: inflammation and neurodegeneration. The latter determines the prognosis of
this disease. MS is the main cause of non-traumatic disability in middle-aged populations.
Findings: The MS-VisualPath Cohort was set up to study the neurodegenerative component of MS using advanced
imaging techniques by focusing on analysis of the visual pathway in a middle-aged MS population in Barcelona, Spain.
We started the recruitment of patients in the early phase of MS in 2010 and it remains permanently open. All patients
undergo a complete neurological and ophthalmological examination including measurements of physical and
disability (Expanded Disability Status Scale; Multiple Sclerosis Functional Composite and neuropsychological tests),
disease activity (relapses) and visual function testing (visual acuity, color vision and visual field). The MS-VisualPath
protocol also assesses the presence of anxiety and depressive symptoms (Hospital Anxiety and Depression Scale),
general quality of life (SF-36) and visual quality of life (25-Item National Eye Institute Visual Function Questionnaire with
the 10-Item Neuro-Ophthalmic Supplement). In addition, the imaging protocol includes both retinal (Optical Coherence
Tomography and Wide-Field Fundus Imaging) and brain imaging (Magnetic Resonance Imaging). Finally, multifocal
Visual Evoked Potentials are used to perform neurophysiological assessment of the visual pathway.
Discussion: The analysis of the visual pathway with advance imaging and electrophysilogical tools in parallel with
clinical information will provide significant and new knowledge regarding neurodegeneration in MS and provide new
clinical and imaging biomarkers to help monitor disease progression in these patients.
Keywords: Multiple Sclerosis, Visual pathway, Neurodegeneration, Cohort studiesFindings
Background
Multiple Sclerosis (MS) is a chronic immune-mediated
disease involving the Central Nervous System (CNS). The
prototypical lesions are acute inflammatory plaques, pri-
marily in white matter, that cause demyelination and sec-
ondary local axonal damage. These focal lesions are
responsible for clinical relapses, the hallmark of the dis-
ease [1]. In fact, most patients have an initial relapsing-
remitting (RR) course featuring clinical relapses followed
by periods of clinical remission. However, after 15–20* Correspondence: pvilloslada@clinic.ub.es
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article, unless otherwise stated.years, 65% of patients develop a secondary progressive
(SP) phase of the disease characterized by progressive dis-
ability independent of relapses [2]. Moreover, some pa-
tients experience a primary progressive (PP) form of the
disease with areas of inflammation visible on magnetic
resonance imaging (MRI) presenting as a gradual accumu-
lation of disability without relapses [3]. As such, relapses
cannot completely account for the disability seen in MS.
Both histopathological and imaging studies have suggested
that diffuse brain damage parallels focal brain damage
from MS onset. Furthermore, inflammatory and neurode-
generative mechanisms have been shown to explain dif-
fuse brain damage that involves grey and white matter [4].
Thus, the classical concept stating that focal inflammation
leads to secondary axonal damage has been reconceiveded Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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independently from inflammation in MS [5]. In fact, neu-
roaxonal damage is considered to be the main cause of
progressive and permanent disability in MS [6]. Immuno-
modulatory treatments are useful for relapses in the acute
inflammatory phase; they prevent disability due to local
neuroaxonal damage after relapses but not disability as a
consequence of the chronic diffuse neurodegeneration of
the disease [3]. For this reason they are effective in the RR
phase of MS but not in the SP phase and PP forms [5].
Thus, it is important to consider MS as both an in-
flammatory and neurodegenerative disease and therefore
critical to clarify the mechanisms behind these processes
to promote the development of neuroprotective and re-
generative therapies. Biomarkers of axonal damage are
also needed to assess the efficacy of these new therapies.
In the clinical setting, disability is evaluated by Expanded
Disability Status Scale (EDSS), which measures neuro-
logic impairment across 8 functional systems. Theoretic-
ally, neuroprotective drugs would provide higher benefit
in the early phase of the disease because once significant
disability is present, corresponding to high EDSS scores
(>4.0), it may be too late for protection. Consequently,
the aims of this cohort are to evaluate neurodegenera-
tion in MS and to develop clinical and imaging bio-
markers of disease severity from the early to the late
phases of the disease.
Rationale: studying neurodegeneration in MS by focusing
in the visual pathway
We decided to study neurodegeneration in MS by focusing
on the visual pathway for several reasons. First, the visual
system is highly susceptible to damage from MS. Optic
Neuritis (ON) is a common ophthalmological disorder in
these patients [7] and 1 out of 3 MS patients suffer from
visual impairment [8]. Moreover, the visual pathway can
also be targeted by MS despite a history of prior optic neur-
itis [9]. Second, the visual pathway can be functionally eval-
uated with Visual Evoked Potentials (VEP) [10] and visual
function tests, namely visual acuity (VA), visual field and
color vision. Structural damage to the anterior and poster-
ior visual pathway can be evaluated by Optical Coherence
Tomography [11-13] (OCT) and by optic nerve and brain
MRI [14-17]. Third, some OCT parameters such as Retinal
Nerve Fiber Layer thickness have moderate to high correla-
tions with brain atrophy [18,19]. Brain atrophy is the most
accepted subrogate marker of neurodegeneration in MS
and is a predictor for subsequent cognitive decline in MS
[20]. The moderate correlation between the retinal nerve
fiber layer (RNFL thickness) and cognitive function [21] re-
inforces the role of visual pathway outcomes as biomarkers
of MS. Moreover, both axonal (RNFL) and neuronal com-
ponents, usually estimated by quantifying the thickness of
the Ganglion Cell layer and Inner plexiform layer (GCIP)due to technical limitations to separate these two layers,
can be used to monitor neurodegeneration since each
showed appropriate correlations with cortical grey matter
(p = 0.01 and p = 0.04, respectively) and caudate (p = 0.04
and p = 0.03, respectively) volumes in the eyes of patients
with MS without a history of optic neuritis [13]. More re-
cently, Saidha and colleagues presented moderate correla-
tions between GCIP loss and whole brain atrophy (r: 0.44),
atrophy in grey matter (r = 0.37), white matter (r = 0.28),
and thalamic (r = 0.38) regions of the brain over a 4-year
follow-up study [22].
The aim and objectives
We aim to study neurodegeneration in MS because it de-
termines prognosis and patients’ daily activity. We focus
on the afferent visual pathway since it is frequently af-
fected in MS and easily measurable both functionally and
structurally. The MS-VisualPath cohort has two main pur-
poses. The first objective is to evaluate the diffuse axonal
damage in the early phase of RR-MS form. We aim to as-
sess the role and interplay of different mechanisms includ-
ing diffuse demyelination, neuroinflammation and axonal
degeneration due to acute inflammation, and diffuse
trans-synaptic neuroaxonal damage development. The
second objective is to identify new biomarkers of neurode-
generation, including brain and retina image biomarkers,
as well as more robust clinical markers of disability. Since
we began including mfVEP in February 2013, a limited
number of participants have baseline values available. For
this reason, the role of mfVEP as a biomarker will be eval-
uated as an exploratory objective.
Methods
The MS-VisualPath cohort
The MS-VisualPath cohort is an ongoing prospective co-
hort study of patients with MS conducted at the Hospital
Clinic of Barcelona, Spain. This hospital provides health-
care to nearly 300,000 habitants in Barcelona. Patients
with MS who are followed-up in the center are invited if
they fulfil the study criteria. However, patients who are re-
ferred to the neurologist of this center can also be in-
cluded if they show interest in participating. This is an
ongoing prospective cohort that started in December
2010 and has permanently open recruitment.
The cohort includes preferentially men or women (age
18–55 years) with RRMS or Clinically Isolated Syndrome
(CIS) accordingly to McDonalds criteria [23,24] with or
without history of prior ON. Although the primary object-
ive was to evaluate neuroaxonal damage in early MS (CIS
and RR), a group of patients with primary (PP) and second-
ary (SP) progressive forms were recruited to evaluate differ-
ences. Patients need to fulfil the minimum reliability
criteria for OCT and visual field. The reliability criteria for
OCT includes a well-centered optic disc and fovea, well
Martínez-Lapiscina et al. BMC Research Notes 2014, 7:910 Page 3 of 11
http://www.biomedcentral.com/1756-0500/7/910defined RNFL and Retinal Pigment Epithelium, no artifacts,
proper illumination of the fundus, signal strength >20 and
no errors in the RNFL and macular automatic segmenta-
tion algorithms, thereby fulfilling OSCAR-IB [(O) = obvious
problems including violation of the protocol; (S) poor signal
strength defined as <15 dB; (C) wrong centration of scan;
(A) algorithm failure; (R) retinal pathology other than MS
related; (I) illumination; and (B) beam placement] criteria
for OCT acquisition [25]. The criteria for visual field are a
proportion of false positives and false negatives lower than
20% and 33%, respectively, and fixation losses lower than
20%.
Exclusion criteria are: 1) any progressive neurological
disorder (other than MS), any medical condition or limit-
ing psychiatric disease (including depression, bipolar and
psychosis) that may interfere with the subject’s ability to
cooperate and comply with study procedures; 2) any state
of immunosuppression different from MS; 3) any ophthal-
mological causes for retinal damage different from MS or
major difficulties for OCT evaluation such as severe
refractive defects [myopia > −6.0 dp or axial eye length
>26 mm; hypermetropia > 5 dp; cylinder > 3 dp], optic disk
drusen, cataracts, glaucoma; 4) current or previous treat-
ment with a drug involved in toxic neuropathy, such as
ethambutol, isoniazid, linezolid, gentamycin, chloram-
phenicol, vincristine, penicilamine; 5) recent history of
acute optic neuritis (<6 months). Patients with ON can be
recruited after 6 months of the acute episode; 6) previous
diagnosis of Diabetes Mellitus or impaired fasting glucose
(≥126 mg/dL or ≥ 200 mg/dL after oral glucose tolerance
test); 7) inability to undergo MRI: reduced renal clearance
(screening: GFR < 45 ml/min), history of severe hypersen-
sitivity to gadolinium-DTPA, claustrophobia and 8) his-
tory of substance abuse in the last 5 years including
alcoholism (>40 g/day for women and 60 g/day for men)
and severe tobacco use (>20 cigarettes/day). Patients with
acute relapses or systemic steroid treatment in the pre-
vious month can be included 2 months after the acute
episode.
The selection process begins by extracting names of
potential participants from the electronic medical
records (EMR) of the Hospital Clinic. The EMR are
checked to corroborate that they meet study eligibility
criteria. Candidates are approached during their clinical
visits and if they show interest in enrolling in the cohort,
an interview with the researcher is scheduled. The re-
searcher explains the purpose, visits, and diagnostic tools
included in the protocol. If the patient agrees to partici-
pate, he/she signs an informed consent and a screening
ophthalmological visit is scheduled to evaluate if the par-
ticipant fulfils the reliability criteria for OCT and visual
fields. Most MS patients approached in this way agreed
to enrol in the study (Figure 1). Baseline features of the
participants are displayed in Table 1.Ethics
The Research Ethics Committee approved the study
protocol on April 7th, 2009 (Reference: 4905/2009). Data
will be kept in accordance with the Spanish Data Protec-
tion Law 15/1999 to protect patient confidentially.Data collection
Neurological assessment At baseline, we administer a
survey including a set of relevant demographic and clin-
ical variables: sex, date of birth, education level, profes-
sion, date of MS onset, date of MS diagnosis, disease
subtype, history of prior ON, number of relapses in the
prior 2 years before inclusion and disease-modifying
therapies for MS.
Disease activity is clinically measured by an annualized
rate of relapses and disease severity by EDSS [26] and
Multiple Sclerosis Functional Composite (MSFC) [27].
EDSS measures neurological impairment within 8 Func-
tional Systems (pyramidal, cerebellar, brainstem, sensory,
bowel & bladder, visual, cerebral, and other) to provide
an overall EDSS ranging from 0 (normal) to 10 (death
due to MS) [26]. On the contrary, MSFC measures
neurological disability and focuses on three major clin-
ical dimensions of MS, namely arm/hand function, leg
function/ambulation and cognitive function. MSFC in-
cludes the timed 25-foot walk (T25FW) to evaluate
lower extremity function, the timed nine-hole peg test
(9HPT) to measure upper extremity function, and the 3-
second version of the paced auditory serial addition test-
3 (PASAT) to assess neuropsychological function [27].
The PASAT test evaluates speed of information process-
ing (executive function), which is the most common and
early sign of MS-related cognitive impairment [28]. As
the MS Task Force recommends, each raw subscore is
converted to a Z-subscore by normalizing to a reference
population and then averaged to provide a normalized
overall MSFC score [27]. Two-trained neurologists carry
out the neurological examinations of participants. We
also collect the annualized rate of relapse to clinically
measure the disease activity.
In the MS-VisualPath cohort, we estimate cognitive
impairment using the Brief Repeatable Battery-Neuro-
psychology (BRB-N) [29], which includes cognitive tasks to
evaluate immediate and delayed verbal memory (Selective
Reminder Test - SRT), immediate and delayed visual mem-
ory (10/36 Spatial Recall - SPART), executive function
(Paced Auditory Serial Addition Test - PASAT - and the
Symbol Digit Modality Test - SDMT) and verbal fluency
(Word List Generation - WLG), using Spanish norma-
tive cut-offs [30]. Two neurologists administer BRB-N
after receiving additional training by an MS neurologist
experienced in the cognitive evaluation of MS using
neuropsychological batteries.
Figure 1 Displays the flow-chart of participants. It shows the participants dropped during the recruitment process as well as those dropped
during the follow-up.
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and low contrast visual acuity (LCVA). Since ON attacks
(even subclinical episodes) are frequent in MS, we prefer
to evaluate monocular VA. Moreover, this approach facili-
tates assessment of functional-structural correlations with
OCT and VEP. After correcting for any refractive errors,
including in patients with eyeglass prescriptions, we assess
HCVA and LCVA with Early Treatment for Diabetic Ret-
inopathy Study (ETDRS-Precision Vision, LaSalle, IL) vis-
ual acuity charts and new Low-Contrast Sloan Letter
Charts (LCSLC-Precision Vision, LaSalle, IL), respectively.
ETDRS and LCSLC charts are printed on a 14 ½ × 13 1/
2–inch durable laminated board. ETDRS charts have
black letters of progressively smaller size on a white back-
board, and each line represents a different VA. LCSLC
have grey letters of progressively lower contrast on a white
backboard and each line represents a certain amount of
contrast sensitivity. We selected 2.5% and 1.25% contrast
levels as representative values of LCVA. These levels ofcontrast have been successfully used in MS to assess visual
function [31-33]. A lighting level of 80–100 foot-candles
measured at the white non-letter portions of the charts is
maintained during the visual acuity evaluation as has been
previously published [31-33]. A trained optometrist asks
participants to read the charts from a distance of 4 meters.
First, the optometrist evaluates monocular high visual
acuity for each eye and after that, low visual acuity inde-
pendently for each eye. The number of correctly identified
letters is recorded for each eye of each participant. Scores
range from 0 to 70 letters. Visual acuity is also scored as a
Logarithm of the Minimum Angle of Resolution (log-
MAR). The formula is VAlogMAR= 0.1 + LogMAR value
of the best line read - 0.02 X (number of letters). Since
some authors suggested that binocular vision may better
reflect visual disability [34], we have added binocular 2.5%
LCVA in the third year evaluation.
Color vision is tested using Hardy, Rand and Rittler
(HRR) pseudoisochromatic plates. The HRR test has 24
Table 1 Baseline features of patients included in the
MS-VisualPath cohort study
Demographic and clinical profile (N: 120)
Sex female n [%] 84 (70)
Age (years) 41.1 ± 9.4
Education >8 years n [%] 107 (89)
Disease duration years 8.6 ± 7.3
Disease Type
CIS n [%] 7 (6)
RRMS n [%] 103 (86)
SPMS n [%] 6 (5)
PPMS n [%] 4 (3)
Treatment at baseline: yes n [%] 90 (75)
Prior optic neuritis n [%] 52 (43.3)
EDSS 1.8 ± 1.2
ARR 2-year prior recruitment 0.4 ± 0.4
CIS: Clinically Isolated Syndrome; RRMS: Relapsing-Remitting MS; SPMS:
Secondary Progressive MS; PPMS: Primary Progressive MS; EDSS: Expanded
Disability Status Scale; ARR: Annualized Relapse Rate.
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are three types of plates: 4 non-scored demonstration
plates; 6 scored screening plates and 14 scored plates for
type and severity assessment. The first four plates (plates
1–4) are used to ensure understanding and enough visual
acuity to perform the task. The 6 screening plates (plates
5–6 with 4 symbols for blue-yellow deficit and plates 7–10
with 6 symbols for red-green) classify eyes as having dys-
chromatopsia or normal color vision. An eye with less
than two errors is considered normal. There is no need to
continue the test if the HRR score is 35 (one error) or 36
(zero errors). We used two errors as a cut-off point to en-
sure a sensitivity of 1.0, as has been previously described
[35]. An eye with two or more errors in the screening
plates has impaired color vision and plates 11–24 should
be administered to determine type and extent of the de-
fect. Plates 11–20 (18 symbols) and plates 7–10 are used
to assess red-green defect with three levels of severities:
mild (plates 7–10 with 6 symbols and plates 11–15 with 8
symbols); moderate (plates 16–18; 6 symbols) and severe
(plates 19–20, 4 symbols). Plates 21–24 (8 symbols) and
plates 5–6 are used to evaluate blue/yellow defect with
three levels of severities: mild (plates 5–6); moderate
(plates 21–22; 4 symbols) and severe (plates 23–24; 4 sym-
bols). The last group of plates in which errors occur estab-
lishes the extent of the color deficit. For instance, if the
last error occurs in either plates 7–10 or 11–15 and there
are no errors in plates 16–20 there is a mild red-green def-
icit. In our study, color vision is evaluated qualitatively
based on the number of errors in the screening plates: an
eye has a color vision deficit if it has at least two errors in
the screening plates. Moreover, color vision was measuredquantitatively based on the number of correctly identified
symbols in the 20 scored HRR plates with a maximum of
36 symbols.
Visual fields are evaluated with Humphrey Field
Analyzer 750 (Carl Zeiss Meditec, Inc) using Swedish
Interactive Threshold Algorithm (SITA) - standard cen-
tral 24–2 protocol. The stimulus is a Goldman size III
(0.43 Deg) with a background luminance of 31.5 Apos-
tlibs. We defined the reliability criteria for this test in
the previous section. Any visual field not matching these
criteria is repeated or excluded after two failed repeti-
tions. An abnormal visual field is defined by a mean de-
viation of the total deviation plot with p < 0.05.
Quality of life assessment We evaluate the quality of
life of MS patients using the SF-36v2™ scale. This health
survey is a multi-purpose short-form scale that includes
physical, mental and social functional health measures
[34]. We also assess the presence of anxiety and depres-
sive symptoms in the cohort, even though we excluded
participants with severe mood disorders. We use the
Hospital Anxiety and Depression Scale (HADS). This
scale, originally proposed by Zigmond AS and Snaith
RP for detecting depression and anxiety in the setting of
hospital medical outpatient clinic [36], has been suc-
cessfully used for evaluating MS patients [37]. HADS
has been validated in the Spanish population [38].
Finally, we use the 25-Item National Eye Institute
Visual Function Questionnaire (NEI-VFQ-25) and the
10-Item Neuro-Ophthalmic Supplement to specifically
assess visual disability. NEI-VFQ-25 includes questions
representing 11 vision-related issues [general vision,
ocular pain, difficulty with near activities, limitations in
distance activities, vision specific limitations in social
functioning due to vision, role limitations due to vision,
dependency on others due to vision, mental health
symptoms due to vision, driving difficulties, color vision
and peripheral vision limitations] and a single-item gen-
eral health-rating question. Scores of NEI-VFQ-25
range from 0 to 100 with higher scores indicating better
visual functioning [39]. The 10-Item Neuro-Ophthalmic
Supplement was designed to target additional aspects
of visual disability among patients with neuro-
ophthalmological conditions such as ON. Scores also
range from 0 to 100 [40]. Both questionnaires have been
previously used in MS [41,42]. All health-related quality of
life surveys are suitable for self-reported administration.
Visual pathway electrophysiological assessment Multi-
focal Visual Evoked Potentials (mfVEP) are recorded
using the monocular VisionSearch1 perimetry system
(Vision Search, Sydney, Australia). The visual stimulus
is generated on a high-resolution LCD display and the
patient should be comfortably seated 35 cm from the
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tricity dartboard pattern comprised of 56 segments.
Each segment contains a 4×4 checkerboard pattern of
black and white squares. The size of each square is pro-
portional to the size of the segment and dependent on
eccentricity. Stimulus conditions require luminance of
146 candela (cd) per m2 for white squares and 1.1 cd/m2
for black squares with a contrast of 99%. Two opposite
binary reversal sequences occur at each of the 56 sites
in the visual field according to a pseudorandom se-
quence. Each stimulation site is modulated in time ac-
cording to a different sequence. The final signal is
computed by cross-correlation of the response evoked
by the sequence stimulation with the sequence itself
for each site or area of visual field. To record, we use
four gold-cup electrodes (Grass Technologies, West
Warwick, RI, USA) placed on the scalp (2 electrodes ei-
ther side of the inion, one electrode 2.5 cm above and
one 4.5 cm below the inion in the midline). Electrical sig-
nals are recorded along 2 channels (differences between
superior and inferior and left and right electrodes). MfVEP
are amplified 1 × 105 times and band-pass filtered 1 Hz to
20 Hz using a Grass 15LT amplifier. The recordings are
collected using monocular stimulation and repeated 6–10
times in order to reduce the signal/noise ratio. Then, cor-
relations between pattern reversal sequences and recorded
electrical signals are performed with Terra™ software (Vi-
sion Search, Sydney, Australia) to obtain responses for
each segment.
The largest peak-trough amplitude within the 70–
210 msec is determined for each channel. For ampli-
tude analysis, the software automatically designates
the wave of maximal amplitude between two channels
and a combined topographic map is created. For la-
tency analysis, the second peak of the largest wave
from two channels of a given visual field segment of
both eyes is automatically selected by a specially de-
signed algorithm. The same channel and same peak
are then used to assess latency for a particular
segment in the other eye. Ultimately, mfVEP deter-
mines inter-eye differences in the latency and ampli-
tude of the cortical response in each segment. It is
also possible to compare latencies and amplitudes of
a patient’s eye and normative data of a healthy
population.
This method for mfVEP performance has shown good
technical feasibility and consistency in a study including
healthy controls and ON patients from two different
countries [43]. Latencies of mfVEP may be useful to dis-
criminate patients with ON at risk of MS progression
[44]. Moreover, some authors have found a strong cor-
relation between latency delay of mfVEP and axonal
damage measured by RNFL [10] and mfVEP amplitude
and disability measured by EDSS [45].Image assessment
Wide-field fundus imaging A trained ophthalmologist
performs a complete indirect ophthalmoscopy after full
mydriasis at baseline. For follow-up assessment, we per-
form wide-field fundus imaging using Optomap200
(Optos®). This optical device consists of a scanning laser
ophthalmoscope that provides images of a 200° field of
the retina without mydriasis. This system images 80% of
the retina in a single shot [46]. Optomap200 has a mod-
erate sensitivity for lesions located posterior to the equa-
tor but low sensitivity for those situated anterior to the
equator [47]. This limitation is explained by the low
image quality in the far temporal and nasal peripheral
retina and the fact that the peripheral superior and infer-
ior peripheral retina cannot be scanned [48].Optical coherence tomography Optical Coherence Tom-
ography is performed for each eye by a trained optometrist
using two OCT systems: the Blue Peak™ Spectral Domain
OCT Spectralis® (Heidelberg Engineering, Germany) and
the 4000 Spectral Domain OCT Cirrus® (Carl Zeiss, Dublin,
US). The protocol for Spectralis was as follows: (1) RNFL
Thickness: raster scan centered on the optic nerve head
(ART = 100 frames; diameter 12°; which equals approxi-
mately a 3.5 mm diameter ring in a normal sized eye) and
(2) Macular Volume: raster scan centered on the fovea
(ART > 9frames; matrix size 20 × 20; 25 sections of 240um;
6 mm ring area; horizontal acquisition). The protocol for
Cirrus was as follows: an optic disc cube 200 × 200 cen-
tered on the disk was used to measure RNFL thickness and
a macular cube 512 × 128 centered on the fovea was used
to assess macular volume (MV) both with signal strength >
5/10. Both optical devices have demonstrated adequate re-
producibility of OCT [49,50] measures although Spectralis
equipment provides TruTrack™ active eye tracking technol-
ogy to further improve reproducibility of measurements.
To be included in the study all OCT needs to fulfil
OSCAR-IB criteria: [(O) = obvious problems including
violation of the protocol; (S) poor signal strength defined
as <15 dB; (C) wrong centration of scan; (A) algorithm
failure; (R) retinal pathology other than MS related; (I)
illumination; and (B) beam placement] [25]. A trained
optometrist performs OCT and assesses whether each
fulfils the OSCAR-IB criteria in our cohort. In cases
where OCT does not fulfil the criteria, acquisition is re-
peated or the data is ultimately excluded. Our criteria
for exclusion includes any ophthalmological causes for
retinal damage other than MS (R) as well as any major
difficulties in OCT evaluation including cataracts and
other opacities leading to poor signal strength (O and S).
Most of our patients have mild retinal atrophy in which
algorithm failures are less probable (A). In our cohort,
most rejections are due to patients moving their heads,
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slices on macular volume scans.
Brain magnetic resonance imaging Brain images are
acquired using a Siemens Trim Trio® 3 Tesla with a 32-
channel phased array coil. The following sequences are
obtained at baseline: a) 3D structural T1-MPRAGE
(Magnetization-Prepared Rapid-Gradient-Echo) [voxel size
0.9 × 0.9 × 0.9 mm3, Field of View (FOV) 220 mm, Flip
angle 9°, Repetition Time (TR): 1970 ms, Echo Time (TE):
2.4 ms, Inversion recovery time (TI): 1050 ms]; b) 3D
Structural FLAIR (Fluid Attenuated Inversion Recovery)
[Voxel size 0,9 × 0,9 × 0,9 mm3, FOV 220 mm, TR:
5000 ms, TE: 393 ms TI: 1800 ms]; c) 2D Axial T1 post
gadolinium [Voxel Size: 0.7 × 0.6 × 3.0 mm3; FOV 240 mm,
TR: 390 ms, TE: 2.65 ms]; d) Single voxel proton-
spectroscopy (H1MRS) [TR 3000 ms, TE 144 ms, volume
of interest (VOI) size 20 × 30 × 20 mm3, including In-vivo
water suppressed (128 averages) and water unsup-
pressed (16 averages) acquisitions]. The H1MRS VOI
was positioned in the visual cortex (inter-hemispheric
fissure, including both calcarine sulci) and in the pre-
central cortex. The absolute N-Acetyl Aspartate [NAA]
in the visual cortex was calculated using LCModel soft-
ware 7; e) Diffusion Tensor Imaging (DTI) [Voxel Size
2.5 × 2.5 × 2.5 mm3; FOV: 240 mm; b-val 1000 s/ mm2,
NG: 30, Nb0: 1, TR: 6900; TE: 89] f ) Coronal T2 fat
saturated spin echo acquisitions for each optic nerve
[Voxel Size 0.5 × 0.5 × 2 mm3, 20 parallel slices trans-
versal to optic nerve, flip angle 120°, TR: 2600 ms and
TE: 83 ms] and Coronal T1 for each optic nerve [Voxel
Size 0.5 × 0.5 × 2 mm3, 20 parallel slices transversal to
optic nerve, flip angle 70°, TR: 483 ms and TE: 4.92 ms]
before and after gadolinium. These sequences are
acquired before GD injection.
During the follow-up, we have made some changes: a)
exclusion of the optic nerve sequences: b) substituting
HARDI (High-Angular Resolution Diffusion Imaging) in
place of DTI scans [2 × 2 × 2 mm3; FOV: 240 mm; b-val
1500 s/mm2, NG: 70, Nb0:6; TR: 12600 ms; TE:112 ms]
because we have found a better track reconstruction
with HARDI (manuscript in preparation) c) adding Rest-
ing State functional MRI (RS-fMRI) [Voxel Size 1.7 ×
1.7 × 3 mm3; TR: 2000 ms; TE: 19 ms; Slices: 40; Flip
angle 90]. The only sequences acquired after gadolinium
injection are 2D Axial T1 post gadolinium and optic
nerve sequences in the old protocol, and 2D Axial T1
post gadolinium in the new one.
Follow-up assessment
Patients are examined yearly for 3 years, but 5-years
follow-up and thereafter are already considered. After
the third follow-up, patients will be asked to enrol in the
2-year extension study. Table 2 shows the data collectedin each follow-up visit in the MS-VisualPath cohort.
Figure 1 shows flow-chart of participants in the MS-
VisualPath cohort. The attrition rate after 2 years of
follow-up is 3.3%. In fact, half of these participants
dropped out because they moved to another region of
Spain (one patient) or another country (one patient).
Statistics
This study collects a wide range of results that will be ex-
amined using the following standard approach. First, we
will perform descriptive statistics to characterize the sample
using absolute numbers and proportions for qualitative var-
iables and mean and standard deviation for quantitative
variables. Data will be tested for normality, homoscedastic-
ity and independence to test assumptions used for paramet-
ric tests. Then, we will perform bivariate analyses using a
X2 test or Fisher test (in case of small samples) for qualita-
tive variables and independent 2-sample t-test or ANOVA
(three or more groups) for quantitative variables. For data
that is not parametric, we will use the U-Mann–Whitney
test. Pearson’s Correlation test or the non-parametric
analogue, Spearman rank order correlation coefficient, will
be used to evaluate correlations. Finally, we will perform
multivariate tests to rule out confusion that is inherent to
cohort studies. Two-tailed p-values <0.05 will be considered
statistically significant. All analyses will be performed with
the Statistical Package IBM-SPSS (SPSS Inc, Chicago, IL,
USA) software version 20.0 or superior.
Findings
Transynaptic degeneration in MS patients: evidence from
the MS-VisualPath cohort
We have evaluated transynaptic degeneration in a cross-
sectional and short-term follow-up study including the
first 100 consecutive MS patients in the MS-VisualPath.
We found that visual cortex volume, NAA in the visual
cortex, and lesion volume within optic radiations signifi-
cantly influenced average RNFL thinning independently
of other confounders, especially optic neuritis. Addition-
ally, patients with severe prior ON had lower visual cor-
tex volume than patients without ON [51].
Retinal periphlebitis is associated with disease severity
Considering our focus on development of biomarkers of
axonal damage, we have found that patients with previous
retinal periphlebitis had a tendency towards a higher disabil-
ity at baseline and disability progression after a 1-year follow
up compared to patients without primary retinal inflamma-
tion. Specifically, these patients showed higher lesion vol-
ume, lower brain volume and lower RNFL thickness [all of
which are surrogate markers of axonal damage] than pa-
tients without primary retinal inflammation [52]. We evalu-
ated the association between periphlebitis and clinical and
paraclinical markers of neurodegeneration, including RNFL
Table 2 Data assessment in the MS-VisualPath Cohort, Barcelona, Spain
Baseline Year 1 Year 2 Year 3 Year 4 Year 5
EDSS and Annualized Relapse Rate X X X X X X
Multiple Sclerosis Functional Composite X X X X X
Quality of Life (SF-36, NEI-VFQ-25 + 10S1) X X X
Anxiety and Depression assessment1 X X X
Neuropsychological Battery (BRB-N) X X X
High (EDTRS) and Low (LCSLC) VA X X X X X X
Color vision test (HRR plates) X X X X X X
Visual Fields X X X
Indirect Funduscopy - Optomap2002 X X X X X X
Multifocal Visual Evoked Potentials2 X X X X X X
Optical Coherence Tomography X X X X X X
Magnetic Resonance Imaging X X X X X X
Included in the protocol on 1 September 2013 and 2February, 2013. EDSS: Expanded Disability Status Scale; MSFC: SF-36: Short Form-36; NEI-VFQ-25 + 10S: 25-Item
National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and the 10-Item Neuro-Ophthalmic Supplement; BRB-N: Brief Repeatable Battery-
Neuropsychology; EDTRS: Early Treatment for Diabetic Retinopathy Study; LCSLC: Low-Contrast Sloan Letter Chart; VA: Visual Acuity; HRR: Hardy Rand and Rittler.
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models adjusted for sex, age, disease duration, and use of
MS treatment considering RP as an independent (predictor)
variable and RNFL, MV, normalized brain parenchymal vol-
ume (and GM / WM volumes), lesion volume and EDSS as
dependent (predicted) variables in separate models. Since
the outcome variables are quantitative, we cannot estimate
true positive and true negative variables and as such, accur-
acy (TP +TN/overall) cannot be calculated.
Color vision impairment is associated with disease severity
In addition, we explored the potential role of color vision
function testing as a marker of disability and neurodegener-
ation. We have found that patients with dyschromatopsia in
non-ON eyes had greater disability and axonal damage than
MS patients with normal color vision at baseline. Moreover,
patients who developed incident dyschromatopsia after 1-
year follow-up displayed more disability progression and
axonal damage than those without dyschromatopsia [53].
We used the same statistical approach that we performed
for retinal periphlebitis to evaluate color vision.
Discussion
It is our belief that the results of the MS-VisualPath Co-
hort study will provide new and significant knowledge
regarding neurodegeneration in MS as well as new clin-
ical and imaging biomarkers to help monitor disease
progression in these patients. However, we acknowledge
some limitations of our study. In the MS-VisualPath co-
hort, all the hypotheses and studies should take into ac-
count the effect of prior ON on visual function testing,
OCT and MRI values. The presence of prior history is
assessed by patient self-report and confirmed after
reviewing the EHR as described in the Optic NeuritisTreatment Trial [54]. However, subclinical ON is diffi-
cult to rule out. In the MS-VisualPath Cohort, we con-
sider optic nerve MRI and OCT acquisitions and visual
field criteria to evaluate subclinical ON. A subject is
considered to have subclinical unilateral ON if all of the
following findings are detected: the presence of unilat-
eral focal signal hyperintensity of optic nerves in two or
more contiguous MRI slices and the presence of abnor-
mal inter-ocular asymmetry both in RNFL thickness
and in mean deviation of visual field. We considered
these asymmetries as abnormal if RNFL thickness or the
visual fields mean deviation were above the mean plus
one standard deviation of inter-ocular asymmetry of
cases with self-reported history of prior ON. The MS-
VisualPath is an open prospective study so new candi-
dates will be also screened by mfVEP, which are very
sensitive in detecting subclinical ON [55]. Furthermore,
our MRI protocol does not include any sequences with
improved sensitivity to detect cortical lesions that may
contribute to axonal damage in the early RRMS, such as
Double Inversion Recovery [56] or Phase Sensitive In-
version Recovery [57]. Nevertheless, our study also has
strengths. In the MS-VisualPath cohort, the neurologic
and ophthalmologic examinations are performed with
validated tools and performed by trained specialists on a
multidisciplinary team (optometrist, ophthalmologist
and neurologist). Another major strength of the MS-
VisualPath cohort is that the retention rate after 2 years
of follow-up is nearly 97%. A high retention rate is a
major methodological requirement in prospective stud-
ies. Finally, these MS patients are frequently followed-
up with in the neurology outpatient consultancy, so the
close monitoring of participants is also strength of the
MS-VisualPath cohort.
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This MS-VisualPath study has provided the opportunity
to study the pathological mechanisms leading to neuro-
degeneration and disability. We have also provided two
easily assessed clinical biomarkers, namely periphlebitis
and dyschromatopsia, related to neurodegeneration. Fu-
ture analyses and results will further extend these objec-
tives. However, we acknowledge that our results should
be externally validated in other cohorts. Thus, collabora-
tions with national and international studies are wel-
come and can be proposed to: pvilloslada@clinic.ub.es.
Scientific proposals must be satisfactorily peer-reviewed
and ethically reviewed and approved. Contact details,
publications and data request are available upon request
(http://www.neuroimmunologybcn.org).
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